Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04387734 · ClinicalTrials.gov registry record · Phase 4
Effects of Ocrevus in Relapsing Multiple Sclerosis
A Phase 4 study of Relapsing Multiple Sclerosis, sponsored by Georgia State University.
- Active
- Registry status
- Phase 4
- Development phase
- 60
- Enrollment target
- 2
- Study locations
NCT04387734 is a Phase 4 study of Relapsing Multiple Sclerosis that is active but no longer recruiting, run by Georgia State University. The registered enrollment target is 60 participants, below the 2,167-participant average among 23 other Relapsing Multiple Sclerosis trials with a reported enrollment target (97% lower). The trial reports 2 study locations across 1 state.
The verdict
NCT04387734, a Phase 4 study of Relapsing Multiple Sclerosis, is active but no longer recruiting, sponsored by Georgia State University.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 4
- Development phase
- 60 participants
- Enrollment target
- 2
- Study locations
Study Summary
The purpose of this study is to test if people with relapsing multiple sclerosis (RMS) can improve ambulatory functions after one-year treatment with Ocrevus in comparison with other Disease Modifying Treatments (DMT). Sixty qualified individuals with RMS will be evenly assigned into two groups: Ocrevus and other DMT. Each group will receive the respective treatment following the FDA regulations over the one-year course. Their ambulatory functions will be assessed five times three months apart. In addition, they will receive brain MRI scans three times six months apart. Their ambulatory functions and MRI measurements will be compared between groups over time to fulfill the purposes of this study.
Conditions Studied
Interventions
- DRUG Ocrelizumab
- DRUG Platform
Study Locations (2)
Georgia
- Georgia State University - Atlanta
- Multiple Sclerosis Center of Atlanta - Atlanta
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2021-02-05 |
| Est. Completion | 2026-02-28 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04387734
The ClinicalTrials.gov registry entry for NCT04387734 describes a study currently listed as active not recruiting, categorized as Phase 4. The registered enrollment target is 60 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,167-participant average among 23 other Relapsing Multiple Sclerosis trials with a reported enrollment target (97% lower). The listed sponsor is Georgia State University, which has 45 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Relapsing Multiple Sclerosis appearing as the primary indexed condition, and to 2 interventions - of which Ocrelizumab is the first listed.
NCT04387734 reports 2 study locations spanning 1 distinct geographic area - top geographies include Georgia.
Frequently Asked Questions
What is clinical trial NCT04387734 about?
NCT04387734 is a clinical study titled "Effects of Ocrevus in Relapsing Multiple Sclerosis". The purpose of this study is to test if people with relapsing multiple sclerosis (RMS) can improve ambulatory functions after one-year treatment with Ocrevus in comparison with other Disease Modifying Treatments (DMT). Sixty qualified individuals with RMS will be evenly assigned into two groups: Ocr...
What is the current status of trial NCT04387734?
This trial is currently active not recruiting. It is a Phase 4 study. The enrollment target is 60 participants. The study started on 2021-02-05. Estimated completion is 2026-02-28.
What conditions does trial NCT04387734 study?
This clinical trial studies the following conditions: Relapsing Multiple Sclerosis.
What interventions are being tested in trial NCT04387734?
The interventions under investigation include: Ocrelizumab (DRUG), Platform (DRUG).
Who is sponsoring clinical trial NCT04387734?
This trial is sponsored by Georgia State University, which has 45 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04387734 being conducted?
This trial has 2 study locations across Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Relapsing Multiple Sclerosis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Prospective Evaluation of Sequencing From antiCD-20 Therapies to Ozanimod
RECRUITING · Phase 4
-
Impact of Ocrelizumab on Cerebrospinal Fluid Biomarkers at Multiple Sclerosis Onset
ACTIVE NOT RECRUITING · Phase 4
-
Study to Evaluate Safety, Efficacy and Pharmacokinetics (PK) of a Modified Regimen of Ublituximab
RECRUITING · Phase 3
-
Comparative PK, PD, Efficacy, and Safety Assessment of the Proposed Ocrelizumab Biosimilar CYB704 and Ocrevus in Participants With Relapsing Multiple Sclerosis
RECRUITING · Phase 3
-
A Study Evaluating the Presence and Concentration of BRIUMVI™ (Ublituximab) in Breast Milk
RECRUITING
-
A Study Evaluating the Real World Experience of Participants Treated With BRIUMVI® (Ublituximab-xiiy) for Relapsing Multiple Sclerosis (RMS)
RECRUITING
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.